Fennec Pharmaceuticals (FENC): Southpoint group files 13G/A showing 0% ownership

Rhea-AI Filing Summary

Fennec Pharmaceuticals Inc. received an amended Schedule 13G (Amendment No. 3) from a group of Southpoint-related entities and individual John S. Clark regarding its Common Shares, no par value. The reporting persons – Southpoint Master Fund, LP; Southpoint Capital Advisors LP; Southpoint Capital Advisors LLC; Southpoint GP, LP; Southpoint GP, LLC; and John S. Clark – each report 0 Common Shares beneficially owned, with 0% of the class and no sole or shared voting or dispositive power. They indicate they now hold ownership of 5 percent or less of the class. The filing is signed by John S. Clark II in multiple related capacities on August 14, 2026.

Key Figures

Beneficial ownership: 0 Common Shares Percent of class: 0 % Sole voting power: 0.00 +3 more

6 metrics

Beneficial ownership 0 Common Shares Reported by each Southpoint reporting person for Fennec Pharmaceuticals Inc.

Percent of class 0 % Row 11 on the cover pages for each reporting person

Sole voting power 0.00 Row 5 on the cover pages for each reporting person

Shared voting power 0.00 Row 6 on the cover pages for each reporting person

Relevant date 06/30/2026 Date shown near the security and CUSIP information

Signature date 08/14/2026 Date of signatures by John S. Clark II for each reporting person

Key Terms

beneficially owned, sole voting power, shared dispositive power, Ownership of 5 percent or less of a class, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: The information required by this item"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"5 | Sole Voting Power 0.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

shared dispositive power financial

"8 | Shared Dispositive Power 0.00 9 0.00 10"

Ownership of 5 percent or less of a class regulatory

"Item 5. | Ownership of 5 Percent or Less of a Class."

Schedule 13G regulatory

"The names of the persons filing this report (the "Reporting Persons")"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

What does Southpoint’s Schedule 13G/A filing mean for FENC?

Southpoint-related entities and John S. Clark report 0 beneficial ownership and 0% of Fennec Pharmaceuticals’ Common Shares, indicating they now hold 5 percent or less of the class and no voting or dispositive power.

How many FENC shares do the Southpoint entities report owning?

The Southpoint entities and John S. Clark report beneficial ownership of 0 Common Shares of Fennec Pharmaceuticals, with 0.00 sole voting power, 0.00 shared voting power, and 0.00 dispositive power in the cover page data.

What percentage of Fennec Pharmaceuticals (FENC) does Southpoint now report?

Each reporting person in the Southpoint group reports owning 0% of the class of Fennec Pharmaceuticals’ Common Shares and confirms Ownership of 5 percent or less of a class under Item 5 of the report.

Who are the reporting persons in this FENC Schedule 13G/A amendment?

The reporting persons are Southpoint Master Fund, LP, Southpoint Capital Advisors LP, Southpoint Capital Advisors LLC, Southpoint GP, LP, Southpoint GP, LLC, and John S. Clark II, all reporting with respect to Fennec Pharmaceuticals’ Common Shares.

When was the Southpoint Schedule 13G/A for FENC signed and as of what date is it reported?

The Schedule 13G/A identifies a relevant date of 06/30/2026 in the heading, and the certifications are signed by John S. Clark II on 08/14/2026 in multiple representative capacities and individually.

What powers over FENC shares does Southpoint report having?

For each reporting person, the filing lists 0.00 sole voting power, 0.00 shared voting power, 0.00 sole dispositive power, and 0.00 shared dispositive power with respect to Fennec Pharmaceuticals’ Common Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:09 PM Accepted by SEC EDGAR 08/14/2026 - 04:05 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Fennec Pharmaceuticals Inc.

(Name of Issuer)

Common Shares, no par value

(Title of Class of Securities)

31447P100

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 31447P100

1

Names of Reporting Persons

Southpoint Master Fund, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 31447P100

1

Names of Reporting Persons

Southpoint Capital Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 31447P100

1

Names of Reporting Persons

Southpoint Capital Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 31447P100

1

Names of Reporting Persons

Southpoint GP, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 31447P100

1

Names of Reporting Persons

Southpoint GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 31447P100

1

Names of Reporting Persons

John S. Clark II

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Fennec Pharmaceuticals Inc.
(b)	Address of issuer's principal executive offices: PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, NC 27709
Item 2.
(a)	Name of person filing: The names of the persons filing this report (the "Reporting Persons") with respect to the Common Shares, no par value (the "Common Shares") of Fennec Pharmaceuticals Inc. (the "Issuer") are: (i) Southpoint Master Fund, LP (ii) Southpoint Capital Advisors LP (iii) Southpoint Capital Advisors LLC (iv) Southpoint GP, LP (v) Southpoint GP, LLC (vi) John S. Clark II
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is: 1114 Avenue of the Americas, 22nd Floor, New York, NY 10036
(c)	Citizenship: Southpoint Master Fund, LP: Cayman Islands Southpoint Capital Advisors LP: Delaware Southpoint Capital Advisors LLC: Delaware Southpoint GP, LP: Delaware Southpoint GP, LLC: Delaware John S. Clark II: United States of America
(d)	Title of class of securities: Common Shares, no par value
(e)	CUSIP No.: 31447P100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 of the cover pages to this Schedule 13G.
(b)	Percent of class: The information required by this item with respect to each Reporting Person is set forth in Row 11 of the cover pages to this Schedule 13G.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by this item with respect to each Reporting Person is set forth in Row 5 of the cover pages to this Schedule 13G.
	(ii) Shared power to vote or to direct the vote: The information required by this item with respect to each Reporting Person is set forth in Row 6 of the cover pages to this Schedule 13G.
	(iii) Sole power to dispose or to direct the disposition of: The information required by this item with respect to each Reporting Person is set forth in Row 7 of the cover pages to this Schedule 13G.
	(iv) Shared power to dispose or to direct the disposition of: The information required by this item with respect to each Reporting Person is set forth in Row 8 of the cover pages to this Schedule 13G.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Southpoint Master Fund, LP

Signature:	/s/ John S. Clark II
Name/Title:	By Southpoint GP, LP, its General Partner, by Southpoint GP LLC, its General Partner, by John S. Clark II, Managing Member
Date:	08/14/2026

Southpoint Capital Advisors LP

Signature:	/s/ John S. Clark II
Name/Title:	By Southpoint Capital Advisors LLC, its General Partner, by John S. Clark II, Managing Member
Date:	08/14/2026

Southpoint Capital Advisors LLC

Signature:	/s/ John S. Clark II
Name/Title:	John S. Clark II, Managing Member
Date:	08/14/2026

Southpoint GP, LP

Signature:	/s/ John S. Clark II
Name/Title:	By Southpoint GP, LLC, its General Partner, by John S. Clark II, Managing Member
Date:	08/14/2026

Southpoint GP, LLC

Signature:	/s/ John S. Clark II
Name/Title:	John S. Clark II, Managing Member
Date:	08/14/2026

John S. Clark II

Signature:	/s/ John S. Clark II
Name/Title:	John S. Clark II, individually
Date:	08/14/2026